Review and clinical perspectives for the use of infliximab in ulcerative colitis.

Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previously demonstrated to be an effective treatment for patients with Crohn's disease who do not achieve the desired response with conventional treatments. Although the etiology of ulcerative colitis (UC) differs from that of Crohn's disease, randomized controlled trials have demonstrated that infliximab is also beneficial for the treatment of moderate to severe UC in patients who are either intolerant of or refractory to immunosuppressant agents or steroids, or those who are steroid-dependent. A review of the literature is followed by practical recommendations regarding infliximab that address the needs of clinicians and UC patients. Where there is a lack of evidence-based information, the expert panel provides its combined opinion derived from the members' clinical experiences.

[1]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[2]  Mark Avigan,et al.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. , 2007, Journal of pediatric gastroenterology and nutrition.

[3]  P. Rutgeerts,et al.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.

[4]  A. Gottlieb,et al.  A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. , 2007, Journal of the American Academy of Dermatology.

[5]  S. Hanauer,et al.  General principles and pharmacology of biologics in inflammatory bowel disease. , 2006, Gastroenterology clinics of North America.

[6]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  D. Furst,et al.  Problems encountered during anti-tumour necrosis factor therapy. , 2006, Best practice & research. Clinical rheumatology.

[8]  A. Akobeng,et al.  Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. , 2006, The Cochrane database of systematic reviews.

[9]  P. Karran.  Thiopurines, DNA damage, DNA repair and therapy-related cancer. , 2006, British medical bulletin.

[10]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[11]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  C. Lees,et al.  Role of infliximab in ulcerative colitis: further questions. , 2006, Inflammatory bowel diseases.

[13]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[14]  P. Rutgeerts,et al.  Short-term response to infliximab in ulcerative colitis and pouchitis: Results from a single-center experience , 2006 .

[15]  F. Aberra.  To be or not to be: infliximab during pregnancy? , 2006, Inflammatory bowel diseases.

[16]  B. Metchock,et al.  Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[17]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[18]  A. Forbes,et al.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial , 2005, Gut.

[19]  C. Brensinger,et al.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.

[20]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[21]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[22]  G. D'Haens.  Infliximab for ulcerative colitis: finally some answers. , 2005, Gastroenterology.

[23]  R. Baldassano,et al.  Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium , 2005, Inflammatory bowel diseases.

[24]  L. Jacobsson,et al.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.

[25]  J. Terdiman,et al.  Infliximab and Semen Quality in Men With Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[26]  P. Anderson.  Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. , 2005, Seminars in arthritis and rheumatism.

[27]  M. Oliva-Hemker,et al.  Infliximab Efficacy in Pediatric Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[28]  R. Baldassano,et al.  Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. , 2005, Journal of pediatric gastroenterology and nutrition.

[29]  G. Lichtenstein,et al.  Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis , 2004, The American Journal of Gastroenterology.

[30]  B. Göke,et al.  Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study , 2004, European journal of gastroenterology & hepatology.

[31]  A. Gasbarrini,et al.  Infliximab in the treatment of steroid-dependent ulcerative colitis. , 2004, European review for medical and pharmacological sciences.

[32]  C. Prantera,et al.  Infliximab in the treatment of severe ulcerative colitis: a follow-up study. , 2004, European review for medical and pharmacological sciences.

[33]  A. Katz,et al.  Infliximab Is Effective in Acute but not Chronic Childhood Ulcerative Colitis , 2004, Journal of pediatric gastroenterology and nutrition.

[34]  B. Göke,et al.  Safety Aspects of Infliximab in Inflammatory Bowel Disease Patients , 2004, Digestion.

[35]  A. Katz,et al.  Infliximab Therapy in Pediatric Crohn's Pouchitis , 2004, Inflammatory bowel diseases.

[36]  S. Travis.  Predicting outcome in severe ulcerative colitis. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[37]  A. Gasbarrini,et al.  Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[38]  P. Hellström,et al.  Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County , 2004, Gut.

[39]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  W. Mow,et al.  High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[42]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[43]  Louis J. Cohen,et al.  Infliximab in Pediatric Ulcerative Colitis: Two-year Follow-up , 2003, Journal of pediatric gastroenterology and nutrition.

[44]  C. Friesen,et al.  Safety of Infliximab Treatment in Pediatric Patients with Inflammatory Bowel Disease , 2003, Journal of pediatric gastroenterology and nutrition.

[45]  A. Zinsmeister,et al.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.

[46]  S. Anker,et al.  Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications. , 2004, Basic research in cardiology.

[47]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee , 2004, American Journal of Gastroenterology.

[48]  S. Targan,et al.  Infliximab in the treatment of medically refractory indeterminate colitis , 2003, Alimentary pharmacology & therapeutics.

[49]  A. Forbes,et al.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial , 2003, Gut.

[50]  R. Modigliani,et al.  Infliximab for refractory ulcerative colitis or indeterminate colitis: an open‐label multicentre study , 2003, Alimentary pharmacology & therapeutics.

[51]  E. Mahé,et al.  CD30+ T‐cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab , 2003, The British journal of dermatology.

[52]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[53]  M. Braun,et al.  Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.

[54]  R. Caprilli,et al.  Infliximab in refractory pouchitis complicated by fistulae following ileo‐anal pouch for ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.

[55]  R. Bailey,et al.  Infliximab salvage therapy after cyclosporine in an acute flare of chronic ulcerative colitis. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[56]  A. Losco,et al.  Drug side‐effects in IBD , 2002, Alimentary pharmacology & therapeutics.

[57]  J. Lewis,et al.  Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis , 2002, American Journal of Gastroenterology.

[58]  P. Lodhavia.  Efficacy of infliximab in the treatment of refractory pouchitis , 2002 .

[59]  C. Prantera,et al.  Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[60]  G. Actis,et al.  Infliximab for treatment of steroid-refractory ulcerative colitis. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[61]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[62]  R. Baldassano,et al.  Infliximab as a Novel Therapy for Pediatric Ulcerative Colitis , 2002, Journal of pediatric gastroenterology and nutrition.

[63]  H. Steinhart,et al.  Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[64]  R. Weinshilboum,et al.  Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide , 2001, Gut.

[65]  W. Chey,et al.  Infliximab for refractory ulcerative colitis , 2001, American Journal of Gastroenterology.

[66]  S. Targan,et al.  Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study , 2001, Inflammatory bowel diseases.

[67]  W. Chey.  Infliximab for patients with refractory ulcerative colitis. , 2001, Inflammatory bowel diseases.

[68]  R. Moreno-otero,et al.  6‐Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid‐dependent inflammatory bowel disease , 2000, European journal of gastroenterology & hepatology.

[69]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[70]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[71]  A. Lavy,et al.  Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. , 1996, Gastroenterology.

[72]  R. Kozarek.  Review article: immunosuppressive therapy for inflammatory bowel disease , 1993, Alimentary pharmacology & therapeutics.

[73]  A. Axon,et al.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. , 1992, BMJ.

[74]  E. Aadland,et al.  [Severe ulcerative colitis]. , 1990, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[75]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[76]  A. Petrie,et al.  Serum levels of C‐reactive protein in Crohn's disease and ulcerative colitis , 1982, European journal of clinical investigation.

[77]  D. Jewell,et al.  Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.

[78]  E. Krawitt.  Ulcerative colitis and pregnancy. , 1959, Obstetrics and gynecology.

[79]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.

[80]  L. Witts,et al.  Cortisone in Ulcerative Colitis , 1954 .

[81]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[82]  S. Truelove.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. , 1954, Gastroenterologia.